RPID
What one share of Rapid Micro Biosystems holds
Laboratory Analytical Instruments
We are leading a global transformation toward fully automated microbial quality control ("MQC") within pharmaceutical manufacturing. Our products safeguard the most complex and critical bioprocessing workflows in the industry, enabling faster, safer, and higher capacity drug production.
Rapid Micro Biosystems’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.76 |
|---|---|
| Profit | −$1.11 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.88 |
| Cash and investments | $0.30 |
| Debt | $0.40 |
| Book value | $0.37 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $44.83 | −$126.11 | $1.92 | −$88.36 | — | −$354.19 |
| 2021 | $1.17 | −$3.94 | $0.16 | −$2.94 | — | $11.17 |
| 2022 | $0.40 | −$1.43 | $0.16 | −$1.54 | — | $3.87 |
| 2023 | $0.52 | −$1.22 | $0.04 | −$1.09 | — | $2.74 |
| 2024 | $0.64 | −$1.08 | $0.03 | −$1.04 | — | $1.73 |
| 2025 | $0.75 | −$1.05 | $0.02 | −$0.71 | — | $0.74 |